Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 17/20 | 0.75 |
| ▸ | CA2 | P00918 | 6/20 | 0.75 |
| ▸ | CA9 | Q16790 | 5/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212435 | 0.94 | STS (0.80) | STSCA2CA9CA1 | |
| SCHEMBL14070736 | 0.94 | STS (0.80) | STSCA2CA9CA1 | |
| SCHEMBL4212438 | 0.94 | STS (0.80) | STSCA2CA9CA1 | |
| SCHEMBL1258193 | 0.90 | STS (0.78) | STSCA2CA9CA1 | |
| SCHEMBL1258427 | 0.90 | STS (0.75) | STSCA2CA9 | |
| SCHEMBL1257203 | 0.90 | STS (0.89) | STSCA2CA9 | |
| SCHEMBL1258825 | 0.88 | STS (0.72) | STSCA2CA9 | |
| SCHEMBL1259376 | 0.88 | STS (0.74) | STSCA2CA9CA1 | |
| SCHEMBL1258804 | 0.87 | STS (0.70) | STSCA2CA9 | |
| SCHEMBL1258414 | 0.87 | STS (0.71) | STSCA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42132-E1 | have special action with respect to tubulin polymerization inhibition and can be used for treating prostate cancer, breast cancer, colon cancer, non-small-cell-lung cancer, or primary dermal microvascular endothelial cell proliferation; 2-methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-yl sulfamate | STERIX LIMITED (GB) | 2011-02-08 | — | — | US | claimed |
| EP-1594886-B1 | ANTITUMORAL D-HOMOESTRA-1, 3, 5 (10)-TRIEN-3-YL 2-SUBSTITUTED SULFAMATES | STERIX LTD (GB) | 2008-08-27 | — | — | EP | claimed |
| US-7244762-B2 | For therapy of prostate cancer | STERIX LIMITED (GB) | 2007-07-17 | — | — | US | claimed |
| US-20060154985-A1 | Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates | STERIX LIMITED (GB) | 2006-07-13 | — | — | US | claimed |
| US-RE42132-E1 | have special action with respect to tubulin polymerization inhibition and can be used for treating prostate cancer, breast cancer, colon cancer, non-small-cell-lung cancer, or primary dermal microvascular endothelial cell proliferation; 2-methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-yl sulfamate | STERIX LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-7244762-B2 | For therapy of prostate cancer | STERIX LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20060154985-A1 | Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates | STERIX LIMITED (GB) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154985-A1 | Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates | TUBB1, TUBA1A, TUBB3 | STS 27/4885CA2 2548/4885CA9 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.